Skip To Main Content

Explore CD20 CD3

Simultaneous binding of cluster of differentiation (CD)20 on B cells and CD3 on T cells can result in T-cell activation and B-cell killing

CD20: a B-cell surface antigen

CD20 protein on Malignant B cell

CD20 is a transmembrane protein and B-cell surface marker that is involved in the development and differentiation of B cells.1 CD20 is expressed in a majority of B-cell malignancies, including chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.1,2

CD3: a T-cell activator

CD3 on T cell

CD3 is a multimeric protein composed of 4 subunits (γ, δ, ε, ζ), which are part of the T-cell receptor (TCR) complex on the surface of T cells. Engagement of CD3 induces downstream signaling events that result in T-cell activation.3

Simultaneously binding CD20 and CD3

Binding CD20 and CD3

Binding CD20 on B cells and CD3 on T cells can engage T cells and redirect their activity against B cells. T-cell activation—a result of the CD20-CD3 interaction—promotes the proliferation/expansion of pre-existing T cells, which may further contribute to the depletion of B cells.4-5

    • Naeim F, Rao PN, Song SX, Grody WW. Principles of immunophenotyping. In: Atlas of Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches. London, UK: Academic Press; 2013:25-46.

      Naeim F, Rao PN, Song SX, Grody WW. Principles of immunophenotyping. In: Atlas of Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches. London, UK: Academic Press; 2013:25-46.

    • Prevodnik VK, Lavrenčak J, Horvat M, Novakovič BJ. Diagn Pathol. 2011;6:33. PMID: 21486448

      Prevodnik VK, Lavrenčak J, Horvat M, Novakovič BJ. Diagn Pathol. 2011;6:33. PMID: 21486448

    • Davis MM. Cell. 2002;110:285-287. PMID: 12176315

      Davis MM. Cell. 2002;110:285-287. PMID: 12176315

    • Bacac M, Klein C, Umana P. Oncoimmunology. 2016;5:e1203498. PMID: 27622073

      Bacac M, Klein C, Umana P. Oncoimmunology. 2016;5:e1203498. PMID: 27622073

    • Sun LL, Ellerman D, Mathieu M, et al. Sci Transl Med. 2015;7:287ra70. PMID: 25972002

      Sun LL, Ellerman D, Mathieu M, et al. Sci Transl Med. 2015;7:287ra70. PMID: 25972002

    Antibodies icon

    Emerging development platforms

    Discover our broad range of antitumor modalities.

    Microscope icon

    Discover cancer biomarkers

    Learn more about the importance of cancer biomarkers.